Elevated plasma N-terminal ProBNP levels in unmedicated patients with major depressive disorder

Neuroscience Letters

Volumn 417, Issue 3, 2007, Pages 322-325

  Politi, Pierluigi ^a   Minoretti, Piercarlo ^a   Piaggi, Noemi ^a   Brondino, Natascia ^a   Emanuele, Enzo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cardiovascular risk; ELISA; Major depressive disorder; Natriuretic peptides; Schizophrenia

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; NEUROHORMONE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA;

ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SCHIZOPHRENIA; UP-REGULATION;

EID: 34247118736     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2007.02.056     Document Type: Article

References (27)

1. Albers S., Mir T.S., Haddad M., and Laer S. N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. Clin. Chem. Lab. Med. 44 (2006) 80-85
2. Bunevicius R., Varoneckas G., Prange Jr. A.J., Hinderliter A.L., Gintauskiene V., and Girdler S.S. Depression and thyroid axis function in coronary artery disease: impact of cardiac impairment and gender. Clin. Cardiol. 29 (2006) 170-174
3. Carnahan R.M., and Perry P.J. Depression in aging men: the role of testosterone. Drugs Aging 21 (2004) 361-376
4. Carney R.M., Freedland K.E., Miller G.E., and Jaffe A.S. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J. Psychosom. Res. 53 (2002) 897-902
5. Chang A.Y., Abdullah S.M., Jain T., Stanek H.G., Das S.R., McGuire D.K., Auchus R.J., and de Lemos J.A. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J. Am. Coll. Cardiol. 49 (2007) 109-116
6. Deng Y., and Kaufman S. The influence of reproductive hormones on ANF release by rat atria. Life Sci. 53 (1993) 689-696
7. Glassman A., Shapiro P.A., Ford D.E., Culpepper L., Finkel M.S., Swenson J.R., Bigger J.T., Rollman B.L., and Wise T.N. Cardiovascular health and depression. J. Psychiatr. Pract. 9 (2003) 409-421
8. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
9. Hennekens C.H., Hennekens A.R., Hollar D., and Casey D.E. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 150 (2005) 1115-1121
10. Huang P.H., Leu H.B., Chen J.W., Wu T.C., Lu T.M., Ding Y.A., and Lin S.J. Comparison of endothelial vasodilator function, inflammatory markers, and N-terminal pro-brain natriuretic peptide in patients with or without chronotropic incompetence to exercise test. Heart 92 (2006) 609-614
11. Kistorp C., Raymond I., Pedersen F., Gustafsson F., Faber J., and Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293 (2005) 1609-1616
12. Lett H.S., Blumenthal J.A., Babyak M.A., Sherwood A., Strauman T., Robins C., and Newman M.F. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom. Med. 66 (2004) 305-315
13. Magnusson M., Melander O., Israelsson B., Grubb A., Groop L., and Jovinge S. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 27 (2004) 1929-1935
14. Mockel M., Muller R., Vollert J.O., Muller C., Carl A., Peetz D., Post F., Kohse J.K., and Lackner J.K. Role of N-terminal pro-B-type natriuretic peptide in risk stratification in patients presenting in the emergency room. Clin. Chem. 51 (2005) 1624-1631
15. Mueller T., Gegenhuber A., Poelz W., and Haltmayer M. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin. Chim. Acta 341 (2004) 41-48
16. Musselman D.L., Evans D.L., and Nemeroff C.B. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch. Gen. Psychiatry 55 (1998) 580-592
17. O'Connor C.M., Gurbel P.A., and Serebruany V.L. Depression and ischemic heart disease. Am. Heart J. 140 (2000) 63-69
18. O'Donoghue M., and Januzzi Jr. J.L. N-terminal proBNP: a novel biomarker for the diagnosis, risk stratification and management of congestive heart failure. Expert. Rev. Cardiovasc. Ther. 3 (2005) 487-496
19. Overall J.E., and Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 10 (1962) 799-812
20. Politi P., Piccinelli M., Klersy C., Madini S., Segagni L.G., Fratti C., and Barale F. Mortality in psychiatric patients 5-21 years after hospital admission in Italy. Psychol. Med. 32 (2002) 227-237
21. Rajagopalan S., Brook R., Rubenfire M., Pitt E., Young E., and Pitt B. Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. Am. J. Cardiol. 88 (2001) 196-198
22. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., and Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59 (1998) 22-33
23. Sullivan D.R., West M., and Jeremy R. Utility of brain natriuretic peptide (BNP) measurement in cardiovascular disease. Heart Lung Circ. 14 (2005) 78-84
24. Telegdy G. The action of ANP, BNP and related peptides on motivated behavior in rats. Rev. Neurosci. 5 (1994) 309-315
25. Weber M., and Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 92 (2006) 843-849
26. Wiedemann K., Jahn H., and Kellner M. Effects of natriuretic peptides upon hypothalamo-pituitary-adrenocortical system activity and anxiety behaviour. Exp. Clin. Endocrinol. Diabetes 108 (2000) 5-13
27. Wiedemann K., Jahn H., Yassouridis A., and Kellner M. Anxiolytic-like effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. Arch. Gen. Psychiatry 58 (2001) 371-377